Bibliography
- Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000;18:157-62
- Yalcin AD, Cilli A, Bisgin A, et al. Omalizumab is effective in treating severe asthma in patients with severe cadiovascular complications and its effects on sCD200, d-dimer, CXCL8 and IL-1beta levels. Expert Opin Biol Ther 2013;13(9):1335-41
- Criado PR, Antinori LC, Maruta CW, et al. Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol 2013;88(3):355-60
- Triwongwaranat D, Kulthanan K, Chularojanamontri L, et al. Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asian Pac Allergy 2013;3:100-5
- Boer JD, Majoor CJ, Veer C, et al. Asthma and coagulation. Blood 2012;119:3236-44
- Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010;115(6):1121-30
- Hataji O, Taguchi O, Gabazza EC, et al. Activation of protein C pathway in the airways. Lung 2002;180(1):47-59
- Global Initiative for Asthma. GINA Report, Global Strategy for Asthma Management and Prevention. 2012. Available from: www.ginasthma.org
- Zuberbier T, Asero R, Bindslev-Jensen C, et al. Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
- Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006;177(7):4794-802
- Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol 2010;38(1):32-8
- Bard S, Paravisini A, Avilés-Izquierdo JA, et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008;144(12):1662-3
- Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-5
- Niven AS, Argyros G. Alternate treatments in asthma. Chest 2003;123(4):1254-65
- Yalcin AD, Gorczynski RM, Parlak GE, et al. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab 2012;58(1-2):89-96
- Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL10, TGF-beta and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012;2012:720976
- Yalcin AD, Bisgin A, Genc GE, et al. Evaluation of homocysteine, eosinophil cationic peptide, 25(OH) vitamin D, pro-inflammatory IL-1beta and immune modulator OX-2 levels in moderate allergic asthma patients: association with biological treatment (Omalizumab; Anti-IgE) & disease activity. Immunopharmacol Immunotoxicol 2013; Accepted